AYAndreia Yuri Yoshigae

Andreia Yuri Yoshigae

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andreia Yuri Yoshigae has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Are Serum Ferritin Levels a Reliable Cancer Biomarker? A Systematic Review and Meta-Analysis

    by Wilmer Ramírez-Carmona, Beatriz Díaz-Fabregat, Andreia Yuri Yoshigae, Ariana Musa de Aquino, Wellerson Rodrigo Scarano, Anthony César de Souza Castilho, Juliane Avansini Marsicano, Rosana Leal Do Prado, Juliano Pelim Pessan, Leonardo de Oliveira Mendes

    Although serum ferritin (SF) has been shown in several studies to be a potential cancer biomarker, the results are inconsistent. Herein, a systematic review was performed to investigate the clinical SF levels in different types of tumors in order to verify the role of SF levels as a biomarker for cancer diagnosis. The search was performed using the PubMed/Medline, Cochrane Library, and Scopus databases. Observational studies comparing SF levels between healthy adults and patients with cancer were included. The meta-analysis was carried out according to the inverse variance and random effects model. The standardized mean differences (SMDs) were assessed at 95% confidence intervals (CIs). We found that SF was higher in patients with cancer (SMD 3.07; CI 1.96,4.17), especially for head and neck cancer (SMD 3.88; CI 0.42,7.34), lung cancer (SMD 1.72; CI 0.67,2.78), pancreatic cancer (SMD 6.79; CI 5.66,7.91), and renal cell carcinoma (SMD 1.77; CI 0.48,3.05). Moreover, in the advanced stages (Stages III and IV), ferritin levels were higher than in healthy adults (SMD 4.89; CI 2.72,7.06, and SMD 8.40; CI 6.99,9.82, respectively). SF acts as a biomarker for pancreatic cancer, renal cell carcinoma, lung cancer, and head and neck cancer and is a sensitive biomarker for the detection of advanced stages of tumors.